Compare Citius Pharmaceuticals Inc (CTXR) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs STMicroelectronics NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while STMicroelectronics NV trades at $52.14 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 3534.5× Citius Pharmaceuticals Inc's market cap, and STMicroelectronics NV pays a 0.68% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and STMicroelectronics NV for 64 Days on average.
| CTXR | STM | |
|---|---|---|
Market Cap | $13.62M | $48.14B |
Volume | 132,438 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $1.82 | $79.91 |
52-Week Low | $0.48 | $21.20 |
Typical Hold Time | 17 Days | 64 Days |
Enterprise Value | $3.79M | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
STM is trading at $52.06, down 7.33% over 24 hours amid broader tech sector pressure. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a $77.31 consensus price target. Recent earnings have been volatile with two misses and one beat in the last three quarters, while the company maintains strong cash flow generation of $555 million in 2025. STM is positioning for AI data-center revenue growth, targeting over $2 billion by 2027, with recent product launches in automotive imaging and edge AI partnerships.
The outlook remains cautiously optimistic given STM's strategic positioning in AI infrastructure and automotive semiconductors, though near-term margin pressures from facility transitions and competitive dynamics pose risks. The 48% upside to consensus target suggests Wall Street sees recovery potential, but investors should monitor execution on AI revenue targets and margin improvement through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
